Literature DB >> 18569640

Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1.

Anke Meyer1, Andrea Staratschek-Jox, Anette Springwald, Heiner Wenk, Jurgen Wolf, Claudia Wickenhauser, Jörn Bullerdiek.   

Abstract

HMGB1 is a high mobility group protein that can act either as a DNA binding protein or extracellularly as a cytokine-like danger signal. Extracellular HMGB1, either actively secreted or passively released by necrotic cells, is linked to inflammation and cancer. Herein, the results of a study to quantify the expression of HMGB1 in lymphomas by quantitative real-time RT-PCR are presented. HMGB1 expression was analysed in 18 non-Hodgkin lymphomas and two lymphoma cell lines. 11/18 primary lymphomas expressed HMGB1 mRNA at a level exceeding the average of normal lymph nodes. Immunohistochemistry showed that HMGB1 positivity is confined to the lymphoma cells. No correlation between HMGB1 expression and grading was found. However, a high percentage of lymphomas is overexpressing a danger-signalling protein. This protein can support the growth and angiogenesis of lymphoma cells in a paracrine way when released e.g. due to necrosis. Thus it constitutes an interesting therapeutic target as well.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18569640     DOI: 10.1080/10428190802064909

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  18 in total

1.  Downregulation of high mobility group protein box-1 resensitizes ovarian cancer cells to carboplatin.

Authors:  Wen Shu
Journal:  Oncol Lett       Date:  2018-07-30       Impact factor: 2.967

2.  Correlation of HMGB1 expression to progression and poor prognosis of adenocarcinoma and squamous cell/adenosquamous carcinoma of gallbladder.

Authors:  Zilu Shi; Qian Huang; Jian Chen; Pengcheng Yu; Xiaosong Wang; Hong Qiu; Yijie Chen; Yangyang Dong
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

3.  Correlation of High Mobility Group Box-1 Protein (HMGB1) with Clinicopathological Parameters in Primary Retinoblastoma.

Authors:  Mithalesh Kumar Singh; Lata Singh; Neelam Pushker; Seema Sen; Anjana Sharma; Feeroj Ahamad Chauhan; Seema Kashyap
Journal:  Pathol Oncol Res       Date:  2015-06-30       Impact factor: 3.201

Review 4.  High-mobility group box 1 and cancer.

Authors:  Daolin Tang; Rui Kang; Herbert J Zeh; Michael T Lotze
Journal:  Biochim Biophys Acta       Date:  2010 Jan-Feb

5.  Co-treatment with deoxycholic acid and azoxymethane accelerates secretion of HMGB1 in IEC6 intestinal epithelial cells.

Authors:  K Fujii; Y Luo; T Sasahira; A Denda; H Ohmori; H Kuniyasu
Journal:  Cell Prolif       Date:  2009-07-06       Impact factor: 6.831

6.  Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Authors:  Z Sheng Guo; Zuqiang Liu; David L Bartlett; Daolin Tang; Michael T Lotze
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

7.  Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma.

Authors:  Xingjun Yao; Gang Zhao; Hongfa Yang; Xinyu Hong; Li Bie; Guojin Liu
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-07       Impact factor: 4.553

Review 8.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

9.  Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas.

Authors:  Guoqiang Bao; Qing Qiao; Huadong Zhao; Xianli He
Journal:  World J Surg Oncol       Date:  2010-06-26       Impact factor: 2.754

10.  HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma.

Authors:  Banzhou Pan; Dongqin Chen; Jiayuan Huang; Rui Wang; Bing Feng; Haizhu Song; Longbang Chen
Journal:  Mol Cancer       Date:  2014-07-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.